The myelomonocytic/monocytic phenotype of AML blasts would be an important inclusion criterion when enrolling patients and validating the ATP1A1/BCL2L1 and MCL1/BCL2L1 expression as response markers. The gene discussed is ATP1A1; the disease is acute myeloid leukemia.